This is Part Two of a series on Supportive Oligonucleotide Therapy (SOT), a form of antisense oligonucleotide therapy. SOT is a personalized, gene-silencing treatment designed to disrupt pathogens like Lyme disease. Read Part One here. By Maria Marian, ND, MSE The idea of silencing genes to weaken ... The post Targeting Lyme at the genetic level: SOT’s emerging role appeared first on LymeDisease.org.
